QuantiFERON-EBV BCTs SPP RUO

• Based on world-leading QuantiFERON-IGRA technology
• Simulates CD4 + CD8 T-cell responses to EBV nuclear antigen proteins
• Unlock immune response potential for better research insights

As T-cells are becoming increasingly recognized for their role in a wide variety of infections and immunity, the exploration of immune response markers for Epstein-Barr Virus (EBV) infections is becoming the next tool for researching their utility in transplant patients and other settings. 

You can count on the world-leading QuantiFERON-IGRA technology to support your research.

The QuantiFERON-EBV Blood Collection Tubes and QuantiFERON ELISA are for Research Use Only and not for diagnostic use.

The QuantiFERON-EBV Blood Collection Tubes and QuantiFERON ELISA are for Research Use Only and not for diagnostic use. Performance characteristics have not been established yet.

The QuantiFERON-EBV BCTs SPP RUO solution is an original combination of blood collection tubes containing innovative specific peptides formulated to stimulate lymphocytes in heparinized whole blood involved in cell-mediated immunity. Plasma from the stimulated samples can then be used for detection of IFN-γ using a simple ELISA. QuantiFERON-EBV BCTs SPP RUO can unlock new research insights on the immune status of individuals at risk for EBV disease.

The QuantiFERON SPP RUO workflow includes blood collection and processing to generate plasma for the detection of IFN-γ from lymphocytes involved in cell-mediated immunity. The QF-EBV Antigen BCT uses a combination of CD4+ and CD8+ antigens specific to EBV nuclear antigen proteins (EBNA-1, EBNA-3A and EBNA-3B) to stimulate lymphocytes in heparinized whole blood. QuantiFERON Nil and Mitogen BCTs are intended to be used as negative and positive controls in conjunction with the QuantiFERON-EBV Antigen BCT when workflow and donor controls are required.

The QuantiFERON-ELISA is a microplate coated with specific material for determining the concentration of IFN-γ in a human plasma sample (reported in International Units per ml; IU/ml). Analysis of results is performed using the QuantiFERON Software.

Numerous publications and recent research highlight the potential research applications of immune response assays for EBV infections, such as, but not limited to:

• Investigating infection severity in hospitalized transplant patients
• Investigating patient prognosis in intensive care units
• Investigating cell-mediated immune response following EBV infection 
• Investigating immune response in patients with EBV-related malignancies (e.g., autoimmunity and cancer).

Analysis software for QuantiFERON-EBV BCTs SPP RUO is available for download.